Emricasan (IDN-6556)

Catalog No.S7775 Batch:S777506

Print

Technical Data

Formula

C26H27F4N3O7
Molecular Weight 569.50 CAS No. 254750-02-2
Solubility (25°C)* In vitro DMSO 100 mg/mL (175.59 mM)
Ethanol 100 mg/mL (175.59 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Emricasan (IDN-6556, PF 03491390, PF-03491390) is a potent irreversible pan-caspase inhibitor. Emricasan is an inhibitor of Zika virus infection.
Targets
caspase [1]
In vitro Emricasan (IDN-6556), also called PF-03491390, is an inhibitor of activated caspases with sub- to nanomolar activity in vitro. It shows neuroprotective activity for hNPCs but does not suppress ZIKV replication.
In vivo In the murine NASH model, stellate cell activation and hepatic fibrogenesis are attenuated by administration of Emricasan (IDN-6556), a pan-caspase inhibitor. It decreases liver injury but not metabolic derangement in NASH and also ameliorates inflammation. This compound is currently being evaluated in phase 2 clinical trials for the reduction of hepatic injury and liver fibrosis caused by chronic HCV infection.

Protocol (from reference)

Cell Assay:[2]
  • Cell lines

    Astrocytes

  • Concentrations

    9 μM

  • Incubation Time

    1 h

  • Method

    Astrocytes are mock-infected, treated with DMSO or treated with 2 μM niclosamide, 92 μM PHA-690509, 9 μM emricasan (IDN-6556), or a combination of 92 μM PHA-690509 and this compound for 1 h before infection with PRVABC59 (MOI = 0.5). Cells are fixed 24 h after infection and stained for ZIKVE and nuclei.
Animal Study:[1]
  • Animal Models

    C57BL/6J mice

  • Dosages

    0.3mg/kg/day

  • Administration

    i.g.

References

  • https://pubmed.ncbi.nlm.nih.gov/24750664/
  • https://pubmed.ncbi.nlm.nih.gov/27571349/

Selleck's Emricasan (IDN-6556) Has Been Cited by 87 Publications

Interferon-β induction heterogeneity during KSHV infection is correlated to levels and activation of the transcription factors ATF2 and RelA, and not IRF3 [ PLoS Pathogens, February 11, 2026, e1013947]
Caspase-Dependent Suppression of Type I Interferon Signaling Promotes Kaposis Sarcoma-Associated Herpesvirus Lytic Replication [ Journal of Virology, April 27, 2018, e00078-18] PubMed: 29514903
Early Detection of Cell Death Using Transmembrane Water Exchange Magnetic Resonance Imaging [ Adv Sci (Weinh), 2026, 13(23):e13317] PubMed: 41405452
ADAR1 regulates dsRNA formation in nuclear and mitochondrial transcripts through editing-dependent and -independent mechanisms [ Cell Rep, 2026, 45(3):117026] PubMed: 41800619
Human induced pluripotent stem cell-derived inner ear organoids reveal hair cell damage and plasticity after cisplatin and gentamicin exposure [ Dis Model Mech, 2026, 19(6)dmm052511] PubMed: 41773293
Andrographolide-induced PANoptosis underlies its multiple organ toxicity in mice [ Toxicol Appl Pharmacol, 2026, 507:117682] PubMed: 41371369
Chidamide synergizes with cisplatin-etoposide to trigger pyroptosis and anti-tumor immunity in diffuse large B-cell lymphoma [ Commun Med (Lond), 2026, 6(1)438] PubMed: 42014876
Statins and genetic inhibition of the mevalonate pathway activate an ATF3-STMN2 regenerative program [ bioRxiv, 2026, 2026.02.23.707492] PubMed: 42051315
SIGLEC12 mediates plasma membrane rupture during necroptotic cell death [ Nature, 2025, 10.1038/s41586-025-09741-1] PubMed: 41225007
Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia [ Cell, 2025, S0092-8674(25)01233-4] PubMed: 41265435

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Jump to: